What does this research mean for the field?

IMNN-001 gene therapy adds clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The central aim is to evaluate the effectiveness of IMNN-001 gene therapy in treating newly diagnosed ovarian cancer.

March 1, 2026

Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.

Key Points

The central aim is to evaluate the effectiveness of IMNN-001 gene therapy in treating newly diagnosed ovarian cancer.
Assessment of clinical findings related to IMNN-001
Evaluation of IL-12-driven immunotherapy
Analysis of the therapeutic combinations with existing immunotherapies.
IMNN-001 shows potential for clinically meaningful impact in therapy groups.
Synergistic effects with other immunotherapies are suggested.
Enhanced intrinsic immune activity is associated with IMNN-001 administration.

Abstract

IMNN-001 gene therapy could add clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. IMNN-001 holds promise for synergistic combinations with immunotherapies requiring intrinsic immune activity.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Premal H Thaker

Stacy Lindborg

Ana Limon

Actions

Institutions

Washington University in St. Louis

Vanderbilt University Medical Center

Froedtert Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study